Successful neutrophil engraftment supported by granulocyte transfusion in adult allogeneic transplant patients with peri-transplant active infection.


Journal

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 10 12 2021
revised: 23 03 2022
accepted: 03 05 2022
pubmed: 17 5 2022
medline: 6 12 2022
entrez: 16 5 2022
Statut: ppublish

Résumé

Active infection at the time of allogeneic hematopoietic stem cell transplantation (HSCT) is a risk for non-relapse mortality (NRM) after HSCT. Granulocyte transfusion (GTX) has been used to prevent or treat life-threatening infections in patients with severe neutropenia. However, data are limited on the clinical benefits of GTX during HSCT. We retrospectively analyzed the transplant outcomes of HSCT patients who had undergone GTX between 2012 and 2020. Altogether, 20 patients with documented infection had received 55 GTXs during HSCT. No adverse events were observed during the GTX infusion. The average number of granulocytes was 0.40 (range, 0.10-1.59) × 10

Identifiants

pubmed: 35577683
pii: S1473-0502(22)00126-4
doi: 10.1016/j.transci.2022.103453
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

103453

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of interest The authors declare that they have no conflict of interest.

Auteurs

Shuntaro Ikegawa (S)

Division of Blood Transfusion, Okayama University Hospital, Okayama, Japan; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Nobuharu Fujii (N)

Division of Blood Transfusion, Okayama University Hospital, Okayama, Japan; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan. Electronic address: nfujii@md.okayama-u.ac.jp.

Keiko Fujii (K)

Division of Blood Transfusion, Okayama University Hospital, Okayama, Japan; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Maiko Kimura (M)

Division of Blood Transfusion, Okayama University Hospital, Okayama, Japan; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Masayuki Matsuda (M)

Division of Blood Transfusion, Okayama University Hospital, Okayama, Japan; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Takumi Kondo (T)

Division of Blood Transfusion, Okayama University Hospital, Okayama, Japan; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Hideaki Fujiwara (H)

Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Noboru Asada (N)

Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Daisuke Ennishi (D)

Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Hisakazu Nishimori (H)

Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Ken-Ichi Matsuoka (KI)

Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Yoshinobu Maeda (Y)

Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH